Recent Updates
Recently added Catalysts

CLBS12

Phase 2

Critical Limb Ischemia | Biologics | Cardiovascular |Lisata Therapeutics, Inc.|Trials Updated: Oct 9, 2024

CLBS12 development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Jul 2015

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment33

FDA Designations

No designations recorded

CLBS12 clinical trials

CLBS12 · 1 trial · 4 indications

Phase 2 1
NCT02501018Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)Critical Limb Ischemia
COMPLETED33 Analytics
PHASE2COMPLETED
Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)
Critical Limb IschemiaUnlock trial analytics

Study Endpoints

Primary Endpoints

Time to continuous CLI-free status
1 year

CLI-free is determined by assessing the Rutherford score (\</=3) by the investigator and a central adjudication committee.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
CLI Due to ASO with CLBS12 + SOCEXPERIMENTALThis group of subjects with CLI due to ASO will be administered with CLBS12 + SOC for collecting efficacy and safety data.
CLI Due to ASO with SOCACTIVE_COMPARATORThis group of subjects with CLI due to ASO will be administered with SOC only.
CLI Due to BD with CLBS12EXPERIMENTALCLBS12 will be administered to patients with CLI due to BD for collecting safety and efficacy data.

Interventions

NameTypeDescription
CLBS12BIOLOGICALIntramuscular transfusion of CLBS12.
SOCDRUGStandard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).
Unlock Study Design Details

Eligibility Criteria

Age Range20 Years to 85 Years
SexALL
Healthy VolunteersNo
Study Sites12

Inclusion Criteria: * subject has CLI caused by ASO or BD Exclusion Criteria: * \< 20 years old

Countries:Japan
Unlock Eligibility Criteria

Frequently asked questions about CLBS12

What is CLBS12?

CLBS12 is an investigational biologic therapy developed by Lisata Therapeutics for critical limb ischemia, a severe form of peripheral artery disease. It has been studied in a Phase 2 clinical trial conducted in Japan that enrolled 33 patients with critical limb ischemia and related vascular conditions.

What is CLBS12 used for in critical limb ischemia?

CLBS12 is being developed for the treatment of critical limb ischemia, a condition in which blood flow to the limbs is severely reduced. The Phase 2 study of CLBS12 also enrolled patients with Buerger disease, also called thromboangiitis obliterans, and atherosclerosis obliterans.

Who is developing CLBS12?

CLBS12 is being developed by Lisata Therapeutics, Inc., a company whose common stock trades under the ticker symbol LSTA. Lisata Therapeutics sponsored the Phase 2 clinical study of CLBS12 in critical limb ischemia conducted in Japan.

What phase is CLBS12 in?

CLBS12 is in Phase 2 clinical development. Its single registered trial, NCT02501018, is a completed Phase 2 study. CLBS12 is investigational and has not been established as an approved therapy for critical limb ischemia.

What clinical trials is CLBS12 in?

CLBS12 has been evaluated in one clinical trial, NCT02501018, titled a Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia. The Phase 2 trial was active-controlled, randomized, enrolled 33 patients in Japan, and is now completed.